Mark Reedy Shirisha Jonnalagadda Komaraiah Palle
10.3389/pore.2021.1609922
Pathol Oncol Res
2021 Dec 20;27:1609922.
human papilloma virus high-risk variant immunotherapy intratumoral injection quadrivalent hpv-l1 vaccine radiation refractory squamous cell carcinoma toll-like receptor 7 agonist
CC BY
https://pubmed.ncbi.nlm.nih.gov/34987310/
Antineoplastic Agents / therapeutic use Carcinoma, Squamous Cell / therapy Genital Neoplasms, Female / therapy Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / therapeutic use Imiquimod / therapeutic use
Antineoplastic Agents / therapeutic use Carcinoma, Squamous Cell / therapy Genital Neoplasms, Female / therapy Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / therapeutic use Imiquimod / therapeutic use Case Reports Adult Aged, 80 and over Carcinoma, Squamous Cell / pathology Carcinoma, Squamous Cell / virology Female Genital Neoplasms, Female / pathology Genital Neoplasms, Female / virology Humans Neoplasm Recurrence, Local / therapy Papillomavirus Infections / complications Papillomavirus Infections / therapy Salvage Therapy / methods Toll-Like Receptor 7 / agonists Antineoplastic Agents Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 TLR7 protein, human Toll-Like Receptor 7 Imiquimod
PMC8720759
34987310
Case Report: Intra-Tumoral Vaccinations of Quadrivalent HPV-L1 Peptide Vaccine With Topical TLR-7 Agonist Following Recurrence: Complete Resolution of HPV-HR-Associated Gynecologic Squamous Cell Carcinomas in Two Patients
2021